Therapeutic nanostructures for pulmonary drug delivery

Javadzadeh, Yousef; Yaqoubi, Shadi

doi:10.1016/b978-0-323-46143-6.00020-8

Cited by 25 publications

(18 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is the first choice for delivering drugs through the pulmonary route, owing to its high efficiency and ability to deliver high volumes of the agent due to liquid-based preparations ( Ali, 2010 ; Haddrell et al., 2014 ; Martin and Finlay, 2015 ).To deliver a drug by nebulization, the drug must first be dispersed in a liquid (usually aqueous) medium. After the application of a dispersing force (either a jet of gas or ultrasonic waves), the drug particles are contained within the aerosol droplets, which are then inhaled ( Javadzadeh and Yaqoubi, 2017 ). There are many types of nebulization-based methods that use different mechanisms to produce aerosols.…”

Section: Inhaled Phage Therapy: a New Era Of Therapeuticsmentioning

confidence: 99%

“…Droplets are formed either by the breakup of surface capillaries or by the collapse of cavitation bubbles within the liquid. Ultrasonic nebulizers produce a more uniform particle size than jet nebulizers but are less widely used due to high pricing ( Flament et al, 2001 ; Rau, 2002 ; Javadzadeh and Yaqoubi, 2017 ). To date, many drugs have been nebulized and given through this technique to reach the lungs and show their desired action.…”

Section: Inhaled Phage Therapy: a New Era Of Therapeuticsmentioning

confidence: 99%

See 1 more Smart Citation

Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections

Wang

Xie

Zhao

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

With respiratory infections accounting for significant morbidity and mortality, the issue of antibiotic resistance has added to the gravity of the situation. Treatment of pulmonary infections (bacterial pneumonia, cystic fibrosis-associated bacterial infections, tuberculosis) is more challenging with the involvement of multi-drug resistant bacterial strains, which act as etiological agents. Furthermore, with the dearth of new antibiotics available and old antibiotics losing efficacy, it is prudent to switch to non-antibiotic approaches to fight this battle. Phage therapy represents one such approach that has proven effective against a range of bacterial pathogens including drug resistant strains. Inhaled phage therapy encompasses the use of stable phage preparations given via aerosol delivery. This therapy can be used as an adjunct treatment option in both prophylactic and therapeutic modes. In the present review, we first highlight the role and action of phages against pulmonary pathogens, followed by delineating the different methods of delivery of inhaled phage therapy with evidence of success. The review aims to focus on recent advances and developments in improving the final success and outcome of pulmonary phage therapy. It details the use of electrospray for targeted delivery, advances in nebulization techniques, individualized controlled inhalation with software control, and liposome-encapsulated nebulized phages to take pulmonary phage delivery to the next level. The review expands knowledge on the pulmonary delivery of phages and the advances that have been made for improved outcomes in the treatment of respiratory infections.

show abstract

Section: Inhaled Phage Therapy: a New Era Of Therapeuticsmentioning

confidence: 99%

Section: Inhaled Phage Therapy: a New Era Of Therapeuticsmentioning

confidence: 99%

Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections

Wang

Xie

Zhao

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…pMDIs are widely available, portable inhalers designed to releases a specific dose of the drug, following depression of an actuator, which the patient then inhales in a single inspiration or via a spacer device. Studies have found that many patients have difficulty in using these devices, due to the required coordination of pressing down on the actuator and inhaling the resultant mist simultaneously [ 66 ]. If patients do not have the required coordination to self-administer their medication using a pMDI, some of the drug is deposited in the mouth and at the back of the throat.…”

Section: Impact Of Drug Delivery Devices On the Extent Of Pulmonary Drug Deliverymentioning

confidence: 99%

Pulmonary Drug Delivery of Antimicrobials and Anticancer Drugs Using Solid Dispersions

et al. 2021

View full text Add to dashboard Cite

It is well established that currently available inhaled drug formulations are associated with extremely low lung deposition. Currently available technologies alleviate this low deposition problem via mixing the drug with inert larger particles, such as lactose monohydrate. Those inert particles are retained in the inhalation device or impacted in the throat and swallowed, allowing the smaller drug particles to continue their journey towards the lungs. While this seems like a practical approach, in some formulations, the ratio between the carrier to drug particles can be as much as 30 to 1. This limitation becomes more critical when treating lung conditions that inherently require large doses of the drug, such as antibiotics and antivirals that treat lung infections and anticancer drugs. The focus of this review article is to review the recent advancements in carrier free technologies that are based on coamorphous solid dispersions and cocrystals that can improve flow properties, and help with delivering larger doses of the drug to the lungs.

show abstract

“…On the other hand a breath-enhanced nebulizer is designed such that it entertains the airflow during inspiration and vents out the expired air outside the device, thereby increasing the output rate and decreasing the administration time. Vibrating mesh nebulizers have a mesh plate attached to them, which vibrates upon the action of the piezoelectric element and breaks the aerosol droplets into fine particles before delivery, thereby increasing the aerosol deposition in the alveoli [82] . There have been newer technologies that sense the breathing pattern of patients and releases drug only when appropriate breathing is detected, for example, AKITA [83] .…”

Section: Marketed Pulmonary Drug Delivery Systemsmentioning

confidence: 99%